Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Subavaliada
O PE mais recente da empresa é -0.52, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 366.56K ações, uma redução de 44.16% em relação ao trimestre anterior.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de -0.47.